XML 85 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Numerator:        
Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. $ (125,300) $ 48,675 $ (258,164) $ 7,350
Denominator:        
Weighted-average basic shares outstanding (in shares) 123,285 106,757 115,307 106,394
Effect of dilutive securities (in shares) 0 1,386 0 1,499
Weighted-average diluted shares outstanding (in shares) 123,285 108,143 115,307 107,893
Basic net (loss) gain per share (in dollars per share) $ (1.02) $ 0.46 $ (2.24) $ 0.07
Diluted net (loss) gain per share (in dollars per share) $ (1.02) $ 0.45 $ (2.24) $ 0.07